← Gansu Longshenrongfa Pharmaceutical Industry overview

Gansu Longshenrongfa Pharmaceutical Industry vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Gansu Longshenrongfa Pharmaceutical Industry Co Ltd (300534.CS)

Q3 2026
▲2▼2

Policy Boost Fades as Profit Slump and Drug Setback Weigh

  • TCM policy tailwind The State Council approved the 15th Five-Year Plan for Traditional Chinese Medicine, a sector-wide boost that sent Longshen Rongfa up 20% on July 13 and again on July 20. This policy support improves the outlook for TCM companies, but the initial price spike may already reflect much of the news.

    This is the main positive force behind the stock's early-period surge.

  • Interim profit drops 40.67% Longshen Rongfa's 2026 interim net profit fell 40.67% year on year to 13.71 million yuan, with revenue down 30.96%. This weak financial performance is a major negative for the stock, as it shows the company's core business is struggling despite policy support.

    This is the most important company-specific negative news that directly impacts valuation.

  • Macao registration for key product Longshen Rongfa's flagship Yuanhu Zhitong Dripping Pills received a Macao registration certificate, allowing sales in Macao and expanding overseas business. While the company says it won't significantly impact near-term performance, it enhances brand and market competitiveness, a modest positive.

    This is a new positive development that could support long-term growth.

  • Drug application not approved Longshen Rongfa's controlling subsidiary's marketing application for brexpiprazole oral dissolving film was not approved. This regulatory setback removes a potential new revenue source and adds uncertainty to the company's product pipeline, weighing on sentiment.

    This is a new negative event that directly affects the company's future prospects.

August 2026
▲2▼2

Policy Boost Fades as Profit Slump and Drug Setback Weigh

  • TCM policy tailwind The State Council approved the 15th Five-Year Plan for Traditional Chinese Medicine, a sector-wide boost that sent Longshen Rongfa up 20% on July 13 and again on July 20. This policy support improves the outlook for TCM companies, but the initial price spike may already reflect much of the news.

    This is the main positive force behind the stock's early-period surge.

  • Interim profit drops 40.67% Longshen Rongfa's 2026 interim net profit fell 40.67% year on year to 13.71 million yuan, with revenue down 30.96%. This weak financial performance is a major negative for the stock, as it shows the company's core business is struggling despite policy support.

    This is the most important company-specific negative news that directly impacts valuation.

  • Macao registration for key product Longshen Rongfa's flagship Yuanhu Zhitong Dripping Pills received a Macao registration certificate, allowing sales in Macao and expanding overseas business. While the company says it won't significantly impact near-term performance, it enhances brand and market competitiveness, a modest positive.

    This is a new positive development that could support long-term growth.

  • Drug application not approved Longshen Rongfa's controlling subsidiary's marketing application for brexpiprazole oral dissolving film was not approved. This regulatory setback removes a potential new revenue source and adds uncertainty to the company's product pipeline, weighing on sentiment.

    This is a new negative event that directly affects the company's future prospects.

Latest
▲2▼2

Policy Boost Fades as Profit Slump and Drug Setback Weigh

  • TCM policy tailwind The State Council approved the 15th Five-Year Plan for Traditional Chinese Medicine, a sector-wide boost that sent Longshen Rongfa up 20% on July 13 and again on July 20. This policy support improves the outlook for TCM companies, but the initial price spike may already reflect much of the news.

    This is the main positive force behind the stock's early-period surge.

  • Interim profit drops 40.67% Longshen Rongfa's 2026 interim net profit fell 40.67% year on year to 13.71 million yuan, with revenue down 30.96%. This weak financial performance is a major negative for the stock, as it shows the company's core business is struggling despite policy support.

    This is the most important company-specific negative news that directly impacts valuation.

  • Macao registration for key product Longshen Rongfa's flagship Yuanhu Zhitong Dripping Pills received a Macao registration certificate, allowing sales in Macao and expanding overseas business. While the company says it won't significantly impact near-term performance, it enhances brand and market competitiveness, a modest positive.

    This is a new positive development that could support long-term growth.

  • Drug application not approved Longshen Rongfa's controlling subsidiary's marketing application for brexpiprazole oral dissolving film was not approved. This regulatory setback removes a potential new revenue source and adds uncertainty to the company's product pipeline, weighing on sentiment.

    This is a new negative event that directly affects the company's future prospects.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 2026
▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

  • Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.

    This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.

  • Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.

    A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.

  • Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.

    Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.

  • US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.

    These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 2026
▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

  • Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.

    This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.

  • Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.

    A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.

  • Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.

    Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.

  • US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.

    These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest
▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

  • Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.

    This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.

  • Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.

    A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.

  • Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.

    Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.

  • US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.

    These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.